Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thiotepa + cyclophosphamide + busulfan conditioning before allo-HSCT for NK/T-cell lymphoma
ChiCTR2500110060Phase 3Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Sep 2025
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of thiotepa, cyclophosphamide and busulfan in natural killer/T-cell lymphoma (NKTL) and Aggressive Natural Killer Cell Leukemia (ANKL), sponsored by Shanghai General Hospital. Primary endpoint: Progression-free survival. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
thiotepacyclophosphamidebusulfan
03
Conditions
natural killer/T-cell lymphoma (NKTL)Aggressive Natural Killer Cell Leukemia (ANKL)
Beyond the preview
Go deeper on ChiCTR2500110060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110060.